With over 1.02 million Aptose Biosciences Inc. (APTO) shares trading Friday and a closing price of $5.47 on the day, the dollar volume was approximately $5.58 million. The shares have shown a positive weekly performance of 9.84% and its price on 08/28/20 gained nearly 8.32%. Currently, there are 76.28M common shares owned by the public and among those 64.23M shares have been available to trade.
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 7 analysts who have offered their price forecasts for APTO have a consensus price objective of $10.57. The analysts have set the share’s price value over the next 12 months at a high of $13.00 and a low of $9.00 should the stock experience a downside. Incidentally, analysts’ outlook for the Aptose Biosciences Inc. stock is 2.00 for the next 12 months. The average price target is -15.89% below its last price level and a downside to the estimated low will see the stock gain 39.22% over that period. But an upside of 57.92% will see the stock hit the forecast high price target while mean target price for the stock is $10.00.
Insiders at the company have transacted a total of 17 times over the past 12 months, according to data filed with the U.S. Securities and Exchange Commission (SEC). 10 of these insider trades were purchases, accounting for 680,000 shares. Insider sales of the common stock occurred on 7 occasions, with total insider shares sold totaling 393,394 shares.
The top 3 mutual fund holders in Aptose Biosciences Inc. are Polar Capital Funds Plc – Biotech, Biotech Growth Trust Plc (The), and Man Funds VI Plc – Man European E. Polar Capital Funds Plc – Biotech owns 1.25 million shares of the company’s stock, all valued at over $6.33 million. Man Funds VI Plc – Man European E bought 0.39 million shares to bring its total holdings to over 0.39 million shares at a value of $1.99 million. Man Funds VI Plc – Man European E now owns shares totaling to 0.45% of the shares outstanding.
Shares of Aptose Biosciences Inc. (NASDAQ: APTO) opened at $5.03, down -$0.02 from a prior closing price of $5.05. However, the script later closed the day at $5.47, up 8.32%. The company’s stock has a 5-day price change of 9.84% and -28.22% over the past three months. APTO shares are trading -3.53% year to date (YTD), with the 12-month market performance up to 128.87% higher. It has a 12-month low price of $1.82 and touched a high of $9.25 over the same period. Currently, 1.02 million shares have been traded, compared to an average intraday trading volume of 817.38K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 7.63%, -2.22%, and -9.23% respectively.
Institutional ownership of Aptose Biosciences Inc. (NASDAQ: APTO) shares accounts for 35.10% of the company’s 76.28M shares outstanding. Mutual fund holders own –, while other institutional holders and individual stakeholders account for — and — respectively.
It has a market capitalization of $441.98M and a beta (3y monthly) value of 1.64. The earnings-per-share (ttm) stands at -$0.61. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.62% over the week and 5.21% over the month.
Analysts forecast that Aptose Biosciences Inc. (APTO) will achieve an EPS of -$0.14 for the current quarter, -$0.13 for the next quarter and -$0.54 for 2018. The lowest estimate earnings-per-share for the quarter is -$0.2 while analysts give the company a high EPS estimate of -$0.1. Comparatively, EPS for the current quarter was -$0.24 a year ago. Earnings per share for the fiscal year are expected to increase by 39.40%, and 37.20% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 7 brokerage firm advisors rate Aptose Biosciences Inc. (APTO) as a “Moderate Buy” at a consensus score of 2.00. Specifically, 7 Wall Street analysts polled rate the stock as a buy, while 0 of the 7 advise that investors “hold,” and 0 rated it as a “Sell.”
Looking at the support for the APTO, a number of firms have released research notes about the stock. Maxim Group stated their Buy rating for the stock in a research note on February 20, 2020, with the firm’s price target at $16. H.C. Wainwright coverage for the Aptose Biosciences Inc. (APTO) stock in a research note released on February 06, 2020 offered a Buy rating with a price target of $9. Piper Sandler was of a view on January 09, 2020 that the stock is Overweight, while RBC Capital Mkts gave the stock Outperform rating on March 01, 2019, issuing a price target of $6. B. Riley FBR on their part issued Buy rating on November 16, 2018.